Related Experiment Video

Updated: Oct 29, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.2K

Tumor infiltrating lymphocytes: current pathways to a standard biomarker in breast cancer

William T Tran1,2, Fang-I Lu3, Roberto Salgado4,5

  • 1Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Canada.

Expert Review of Anticancer Therapy
|July 8, 2021
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Tumor-infiltrating lymphocytesbiomarkersbreast cancertumor immune microenvironment

More Related Videos

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

20.4K
A Simple and Rapid Protocol to Non-enzymatically Dissociate Fresh Human Tissues for the Analysis of Infiltrating Lymphocytes
07:29

A Simple and Rapid Protocol to Non-enzymatically Dissociate Fresh Human Tissues for the Analysis of Infiltrating Lymphocytes

Published on: December 6, 2014

20.2K

Related Experiment Videos

Last Updated: Oct 29, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.2K
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

20.4K
A Simple and Rapid Protocol to Non-enzymatically Dissociate Fresh Human Tissues for the Analysis of Infiltrating Lymphocytes
07:29

A Simple and Rapid Protocol to Non-enzymatically Dissociate Fresh Human Tissues for the Analysis of Infiltrating Lymphocytes

Published on: December 6, 2014

20.2K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.2K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.2K

Articles linked to this work by shared authors, journal, and citation graph.

Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.

The Lancet. Oncology·2026

Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial.

The Lancet. Oncology·2026

Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.

The Lancet. Oncology·2026

Unified definition of integrated diagnostics: a position statement of the EFLM.

Clinical chemistry and laboratory medicine·2026

CT-Based Radiomic Features Predict Cervical Lymph Node Metastasis in Dogs With Oral Malignancy: A Machine Learning Study Using Leave-One-Patient-Out Cross-Validation.

Veterinary and comparative oncology·2026

Stage-related transcriptional changes in HR-positive/HER2-negative breast cancer.

NPJ breast cancer·2026

Prospective patient preference study for chronic lymphocytic leukemia (CLL) treatment attributes impacting patient shared decision-making.

Expert review of anticancer therapy·2026

Adjuvant therapy for resectable gastrointestinal stromal tumors: evidence, controversies, and practical guidance.

Expert review of anticancer therapy·2026

Real-world outcomes of ribociclib treatment in HR-positive/HER2-negative metastatic breast cancer: efficacy, safety, and prognostic factors.

Expert review of anticancer therapy·2026

Salivary duct carcinoma- contemporary nuts and bolts from pathologist perspective.

Expert review of anticancer therapy·2026

Machine learning integrated explainable artificial intelligence in predicting toxicities of enfortumab vedotin in urothelial carcinoma: an exploratory study.

Expert review of anticancer therapy·2026

Overcoming emerging challenges in childhood cancer survivorship: a spotlight on pediatric CNS tumors.

Expert review of anticancer therapy·2026

Computed tomographic Characteristics of Presumed Normal Canine Iliosacral Lymph Nodes.

Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association·2026

Novel lipid nanoparticle in a mRNA cancer vaccine drives tumor control via type I IFNs and effector CD8+ T cells.

Molecular therapy. Nucleic acids·2026

Emerging biomarkers of immune checkpoint inhibitor toxicity in triple-negative breast cancer: a mini-review.

Frontiers in immunology·2026

Durable immunovirological control after sequential mogamulizumab and tucidinostat in relapsed or refractory adult T-cell leukemia/lymphoma.

Frontiers in immunology·2026

Generation of an NG2 targeting bispecific antibody for the induction of T-cell immunity against melanoma.

Journal of translational medicine·2026

Differential peripheral immune dynamics underlie therapeutic response to chemotherapy and chemoimmunotherapy in triple-negative breast cancer.

ImmunoHorizons·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us